The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young…
Category: GLP-1 News
Ryoncil, the first FDA-approved mesenchymal stromal cell therapy
Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the…
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to…
Unexpected Benefit: Popular Weight Loss Drug Ozempic Could Also Help You Drink Less – SciTechDaily
Unexpected Benefit: Popular Weight Loss Drug Ozempic Could Also Help You Drink Less SciTechDaily
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects – LINK nky
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects LINK nky
Weight loss drugs may become harder to get. What does that mean for patients? – WBUR News
Weight loss drugs may become harder to get. What does that mean for patients? WBUR News
The weight-loss drugs being tested in 2025: will they beat Ozempic? – Nature.com
The weight-loss drugs being tested in 2025: will they beat Ozempic? Nature.com
What’s Next for Semaglutide? Beyond Diabetes and Weight Loss – News-Medical.Net
What's Next for Semaglutide? Beyond Diabetes and Weight Loss News-Medical.Net
These discounted versions of popular weight-loss drugs are going away: What to know – USA TODAY
These discounted versions of popular weight-loss drugs are going away: What to know USA TODAY
Why pharma is still far from a treatment for galactosemia
With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia…